Animal Gastroesophageal Reflux Disease Market Report 2026

Animal Gastroesophageal Reflux Disease Market Overview

• Animal Gastroesophageal Reflux Disease market size has reached to $1.98 billion in 2025 • Expected to grow to $2.99 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Rising Humanization Of Pets Drives Growth In The Animal Gastroesophageal Reflux Disease Market • Market Trend: Innovative Diet Solutions For Pets With Gastroesophageal Reflux • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Animal Gastroesophageal Reflux Disease Market?

Animal gastroesophageal reflux disease (GERD) is a condition where stomach acid or bile flows back into the esophagus, causing irritation and inflammation. The condition can lead to symptoms such as vomiting, regurgitation, weight loss, or discomfort during eating. The purpose of diagnosing and treating GERD in animals is to prevent discomfort, improve their quality of life, and avoid complications such as esophagitis, ulcers, or stricture formation. The main product types of animal gastroesophageal reflux disease include treatment and diagnostics. Treatment includes products designed to manage and alleviate the symptoms of gastroesophageal reflux disease (GERD) in animals with medications such as antacids, proton pump inhibitors, and other pharmaceutical products that help to reduce stomach acid and improve digestive health. The modes are categorized into over-the-counter (OTC) and prescription, with types of routes of administration such as oral and injectable. It is used for companion animals and livestock animals. The distribution channels included are veterinary hospitals and clinics, retail pharmacies, and e-commerce.

What Is The Animal Gastroesophageal Reflux Disease Market Growth Forecast?

The animal gastroesophageal reflux disease market size is expected to see strong growth in the next few years. It will grow to $2.99 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of advanced diagnostic techniques such as endoscopy and manometry, increasing focus on nutritional and dietary interventions, rising adoption of otc and prescription drugs, expansion of veterinary e-commerce channels, integration of ai and digital platforms for personalized treatment. Major trends in the forecast period include rising adoption of endoscopy and ph monitoring for gerd diagnosis, increasing use of nutritional supplements and dietary modifications in management, growth in prescription and otc medication availability for companion animals, expansion of minimally invasive surgical interventions for gerd treatment, customized treatment protocols for livestock and companion animals.

Global Animal Gastroesophageal Reflux Disease Market Segmentation

1) By Product: Treatment, Diagnostics 2) By Mode: Over-The-Counter (OTC), Prescription 3) By Route Of Administration: Oral, Injectable 4) By Animal: Companion Animals, Livestock Animal 5) By Distribution Channel: Veterinary Hospitals And Clinics, Retail Pharmacies, E-Commerce Subsegments: 1) By Treatment: Medications, Surgical Interventions, Dietary Modifications, Nutritional Supplements, Antacids 2) By Diagnostics: Endoscopy, Esophageal pH Monitoring, Manometry, Ultrasound, Radiographic Studies, Biopsy Techniques

What Are The Drivers Of The Animal Gastroesophageal Reflux Disease Market?

The increasing humanization of pets is expected to propel the growth of the animal gastroesophageal reflux disease market. Humanization of pets refers to the growing trend where pet owners treat their animals more like human family members, attributing human-like emotions, needs, and behaviors to them. The likeness of pets' humanization is driven by the growing emotional bonds between owners and their pets. This increases the demand for specialized healthcare, premium diets, and wellness products that mirror human standards. The humanization of pets heightens awareness of health issues such as gastroesophageal reflux disease (GERD), prompting more attentive owners to seek veterinary care and driving demand for diagnostics, treatments, and preventive options. For instance, in April 2024, according to the American Pet Products Association, a US-based not-for-profit industry association, 86.9 million households in the US had a pet in 2023-2024, accounting for 66% of households, up from 62% in 2022. Therefore, the increasing humanization of pets is driving the growth of the animal gastroesophageal reflux disease industry. The rising spending on animal healthcare is expected to propel the growth of the animal gastroesophageal reflux disease market going forword. Animal healthcare is the care and treatment given to animals to prevent diseases, diagnose health problems, provide medical treatment, and maintain their overall health and well-being throughout their lives. Spending on animal healthcare is rising because pet owners are increasingly prioritizing preventive and advanced medical care to improve the quality and longevity of their animals’ lives, leading to higher use of veterinary services, diagnostics, and treatments. Animal gastroesophageal reflux disease increases spending on animal healthcare by requiring repeated veterinary consultations, diagnostic tests, long-term medication, and dietary management to control symptoms and prevent complications. For instance, in March 2025, according to the American Pet Products Association, US-based non-profit organization, within total spending in 2024, $39.8 billion was spent on Veterinary Care & Product Sales. Therefore, the rising spending on animal healthcare is driving the growth of the animal gastroesophageal reflux disease industry.

Key Players In The Global Animal Gastroesophageal Reflux Disease Market

Major companies operating in the animal gastroesophageal reflux disease market are Zoetis Inc., VCA Animal Hospitals, Petco Health and Wellness Company Inc., Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Hill's Pet Nutrition Inc., IDEXX Laboratories Inc., Ceva Santé Animale, Virbac S.A., Phibro Animal Health Corporation, Dechra Pharmaceuticals PLC, Blue Buffalo Company Ltd., Vetoquinol S.A., Antech Diagnostics, Heska Corporation, WellPet LLC, McNeil Consumer Pharmaceuticals Co., Wag Labs Inc. , VetPartners Limited, BioZyme Inc., Zomedica Corp., NexGen Pharmaceuticals LLC

Global Animal Gastroesophageal Reflux Disease Market Trends and Insights

Major companies operating in the animal gastroesophageal reflux disease market are developing specialized diets that support gastrointestinal diets to improve digestive health and manage symptoms of gastroesophageal reflux disease in pets. Gastrointestinal support diets are specially formulated pet foods designed to manage and alleviate symptoms of gastrointestinal disorders. These diets typically include easily digestible ingredients, balanced nutrients, and added fibers or probiotics to promote digestive health and overall well-being. For instance, in April 2024, Royal Canin, a USA-based subsidiary of Mars Incorporated and manufacturer of cat and dog food, expanded its veterinary gastrointestinal (GI) portfolio by introducing five new diets designed to improve the gastrointestinal health of pets. These specialized diets, developed in collaboration with researchers, veterinarians, and specialists, focus on addressing GI issues in both dogs and cats, including food-responsive sensitivities and fat-restricted diets. The new offerings include options such as gastrointestinal low-fat, hydrolyzed protein canine and gastrointestinal hydrolyzed protein feline, all formulated with highly digestible ingredients to promote long-term gastrointestinal health.

Regional Outlook

North America was the largest region in the animal gastroesophageal reflux disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Animal Gastroesophageal Reflux Disease Market?

The animal gastroesophageal reflux disease market consists of revenues earned by entities by providing services such as specialized veterinary care, prescription medications, diagnostic testing and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The animal gastroesophageal reflux disease market also includes sales of gastrointestinal support diets, medications, and hydrolyzed protein diets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.